High frequency expressions of CD44 standard and variant forms in non- small cell lung cancers, but not in small cell lung cancers

Journal of Surgical Oncology

Volumn 69, Issue 3, 1998, Pages 128-136

  Kondo, Kazuya ^a   Miyoshi, Takanori ^a   Hino, Naoki ^a   Shimizu, Eiji ^a   Masuda, Noriyuki ^b   Takada, Minoru ^b   Uyama, Tadashi ^a   Monden, Yasumasa ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

Author keywords

CD44 repression; Growth pattern; Immunohistochemistry; RT PCR

Indexed keywords

HERMES ANTIGEN;

ARTICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ANTIGENS, CD44; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0031771618     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199811)69:3<128::AID-JSO3>3.0.CO;2-M     Document Type: Article

References (34)

1. Jalkanen S, Bargatze RF, Herron LR, Butcher EC: A lymphoid cell-surface glycoprotein involved in endothelial-cell recognition and lymphocyte homing in man. Eur J Immunol 1986;16:1195-1202.
2. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC: Lymphocyte recognition of high endothelium: antibodies to distincl epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 1987;105:983-990.
3. Jalkanen S, Jalkanen M: Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 1992; 116:817-825.
4. Carter WG, Mayner EA: Characterization of the class III collagen receptor, a phosphorylated transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 1988;263:4193-4201.
5. Screaton GR, Bell MV, Jackson DG, et al.: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1993;89:12160-12164.
6. Gunthert U, Hofmann M, Rudy W, et al.: New variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
7. Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation [see comments]. Lancet 1992;340:1053-1058.
8. Heider KH, Dammrich J, Skroch AP, et al.: Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993; 53:4197-4203.
9. Koopman G, Heider KH, Horst E, et al.: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 1993;177:897-904.
10. Wielenga VJ, Heider KH, Offerhaus GJ, et al.: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754-4756.
11. Dall P, Heider KH, Hekele A, et al.: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994;54: 3337-3341.
12. Penno MB, August JT, Baylin SB, et al.: Expression of CD44 in human lung tumors. Cancer Res 1994;54:1381-1387.
13. Jackson DG, Schenker T, Waibel R, et al.: Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer 1994;8(suppl):110-115.
14. Hemler M, Mihich E: Fourth annual Pezcoller symposium-Adhesion molecules: Cellular recognition mechanism. Cancer Res 1993;53:2192-2194.
15. Masuda N, Fukuoka M, Matsui K, et al.: Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. J Natl Cancer Inst 1991;83: 1743-1748.
16. Masuda N, Fukuoka M, Takada M, et al.: Establishment and characterization of 20 human non-small cell lung cancer cell lines in a serum-free defined medium(ACL-4). Chest 1991;100:429-438.
17. Gazdar AF, Oie HK: Cell culture methods for human lung cancer. Cancer Genet Cytogenet 1986;19:5-10.
18. Union Internationale Contre Le Cancer (UICC): Sherman CD (chairman): "Manual of Clinical Oncology." 4th Ed. Berlin: Springer-Verlag, 1987.
19. World Health Organization (WHO): "Histological Typing of Lung Tumours." 2nd Ed. Geneva: World Health Organization, 1981.
20. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
21. Kondo K, Tsuzuki H, Sasa M, et al.: A dose-response relationship between the frequency of p53 mutations and tobacco consumption in lung cancer patients. J Surg Oncol 1996;61:20-26.
22. Miyoshi T, Kondo K, Hino N, et al.: The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer. Clinical Cancer Res 1997;3:1289-1297.
23. Grube D: Immunoperoxidase methods: increased efficiency using fluorescence microscopy for 3,3-diaminobenzidine (DAB) stained semithin sections. Histochemisiry 1980;70:19-22.
24. Haynes BF, Liao HX, Patton KL: The transmembrane hyaluronate receptor (CD44): Multiple functions, multiple forms. Cancer Cells 1991;3:347-350.
25. Ariza A, Mate JL, Isamat M, et al.: Standard and variant CD44 isoforms are commonly expressed in lung cancer of the non-small cell type but not of the small cell type. J Pathol 1995;177:363-368.
26. Onodera Y, Shimizu H, Yamashita S, Nishikawa T: Cryofixed, freeze-dried and paraffin-embedded skin enables successful immunohistochemical staining of skin basement membrane antigens. Histochemistry 1992;98:87-91.
27. Sato Y, Mukai K, Watanabe S, et al.: The AMeX method: A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986;125:431-435.
28. Li H, Liu J, Hofmann M, et al.: Differential CD44 expression patterns in primary brain tumours and brain metastases. Br J Cancer 1995;72:160-163.
29. Shtivelman E, Michael Bishop J: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 1991;11:5446-5453.
30. Salmi M, Gron-Virta K, Sointu P, et al.: Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 1993;122:431-442.
31. Fujita N, Yaegashi N, Ide Y, et al.: Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994;54:3922-3928.
32. Combaret V, Lasset C, Frappaz R, et al.: Evaluation of CD44 prognostic value in neuroblastoma: Comparison with the other prognostic factors. Eur J Cancer 1995;31A:545-549.
33. Viallet J, Ihde DC.: Small cell carcinoma of the lung: Clinical and biologic aspects. Crit Rev Oncol Hematol 1991;11:109-135.
34. Camey DN, Gazdar AF, Bepler G, et al.: Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res 1985;45:2913-2923.